1.5.3 Drugs affecting the immune response

Drugs used, not listed here:

Vedolizumab
  • Powder for concentrate for solution for infusion 300mg vial
  • Solution for injection pre-filled pens 108mg/0.68ml
  • Solution for injection pre-filled syringes 108mg/0.68ml

Notes

  1. NICE TA342: Vedolizumab (Entyvio) is recommended, within its marketing authorisation, for treating moderately to severely active ulcerative colitis in adults only if the company provides vedolizumab with the discount agreed in the patient access scheme (June 2015)
  2. NICE TA352: Vedolizumab (Entyvio) is recommended as an option for treating moderately to severely active Crohn's disease (August 2015) only if:
    1. a tumour necrosis factor‑alpha inhibitor has failed (that is, the disease has responded inadequately or has lost response to treatment) or
    2. a tumour necrosis factor‑alpha inhibitor cannot be tolerated or is contraindicated
    3. Vedolizumab is recommended only if the company provides it with the discount agreed in the patient access scheme
Darvadstrocel
  • NICE TA556: Darvadstrocel (Alofisel) is not recommended for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn's disease (January 2019)
Last updated: 24-06-2021

 

Home > Formulary > Chapters > 1. Gastrointestinal > 1.5 Chronic bowel disorders > 1.5.3 Drugs affecting the immune response

 

  • First line
  • Second line
  • Specialist
  • Hospital